<DOC>
	<DOCNO>NCT00623064</DOCNO>
	<brief_summary>RATIONALE : Lapatinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , cisplatin , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving lapatinib together combination chemotherapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose lapatinib give together cisplatin gemcitabine first-line therapy treat patient locally advance metastatic urothelial cancer .</brief_summary>
	<brief_title>Lapatinib , Cisplatin , Gemcitabine First-Line Therapy Treating Patients With Locally Advanced Metastatic Urothelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended dos lapatinib ditosylate administer gemcitabine hydrochloride cisplatin , determine basis acute dose-limiting toxicity course 1 patient locally advance metastatic transitional cell carcinoma urothelial tract . Secondary - To determine relationship drug exposure adverse event patient . - To assess antitumor activity patient . OUTLINE : This multicenter , dose-escalation study lapatinib ditosylate . - Lapatinib ditosylate , cisplatin , gemcitabine hydrochloride : Patients receive oral lapatinib ditosylate daily day 1-28 , cisplatin IV day 2 , gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 . Courses repeat every 4 week absence disease progression unacceptable toxicity recommend dose lapatinib ditosylate determine . - Lapatinib ditosylate , cisplatin , gemcitabine hydrochloride : Subsequently enrol patient receive oral lapatinib ditosylate ( begin one dose level recommend dose determine previous combination ) daily day 1-21 , cisplatin IV day 1 , gemcitabine hydrochloride IV 30 minute . Courses repeat every 3 week absence disease progression unacceptable toxicity . All patient undergo blood sample collection periodically pharmacokinetic analysis . After completion study treatment , patient follow weekly .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove transitional cell carcinoma urothelial tract Metastatic locally advance disease Measurable disease accord RECIST Involvement least one target previously irradiate field Overexpressing HER1 and/or HER2 receptor ( HER2 3+ IHC OR HER2 FISH CISH positive ) No clinical sign CNS involvement PATIENT CHARACTERISTICS : WHO performance status 01 ANC ≥ 1,500/mm³ Thrombocytes &gt; 100,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST/ALT ≤ 3 time ULN Creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception 3 month completion study treatment Cardiac ejection fraction normal Normal 12 lead ECG No serious cardiac illness medical condition within past 6 month include , limited , follow : Documented congestive heart failure Highrisk uncontrolled arrhythmias Angina pectoris require antianginal medication Clinically significant valvular heart disease Evidence transmural infarction ECG Poorly control hypertension ( e.g. , systolic blood pressure [ BP ] &gt; 180 mm Hg diastolic BP &gt; 100 mm Hg ) No peripheral neuropathy &gt; grade 1 Able swallow retain oral medication No malignancy within past 3 year except basal cell squamous cell carcinoma skin carcinoma situ cervix No active uncontrolled infection , serious illness , malabsorption syndrome medical condition , hepatitis , HIV , and/or cirrhosis No psychological , familial , sociological , geographical condition potentially hamper study protocol compliance followup schedule No current active hepatic biliary disease ( exception Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver metastasis stable chronic liver disease ) PRIOR CONCURRENT THERAPY : Recovered effect surgery Intravesicle therapy superficial disease allow Prior neoadjuvant adjuvant chemotherapy allow Must minimum interval six month completion neoadjuvant adjuvant chemotherapy diagnosis metastatic disease No prior chemotherapy metastatic disease No radiotherapy within past 4 week No drug herbal inducer inhibitor CYP3A4 ( e.g. , bergamottin glabridin ) within 10 day prior study treatment receive lapatinib ditosylate therapy No concurrent anticancer therapy investigational agent No concurrent anticancer agents No concurrent treatment investigational therapy disease condition No concurrent prophylactic antibiotic No concurrent prophylactic filgrastim ( GCSF ) At least 14 day since prior concurrent herbal dietary supplement No concurrent consumption grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
</DOC>